MetaCap

NextCure (NXTC) vs ProMIS Neurosciences (PMN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NextCure (NXTC) has outperformed ProMIS Neurosciences (PMN) over the past year, losing 38.6% versus a loss of 69.9%. Over five years, NXTC leads with a -91.1% price change compared with -98.2% for PMN. NextCure is the larger company by market cap ($29.5 million vs $28.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NXTC-38.63%PMN-69.90%
+147%+26%-96%
Nov 21, 20251 yearNov 20, 2026
NXTC-90.73%PMN-98.38%
+24%-40%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NXTC versus PMN key metrics
MetricNXTCPMN
Share price$6.45$3.16
Market cap$29.53M$28.43M
1-day change-4.87%-1.56%
YTD return-54.55%-53.73%
1-year return-38.63%-69.90%
5-year return-91.07%-98.24%
EPS (TTM)$-6.78$-6.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-55.84M$-39.72M
52-week high$15.74$27.40
52-week low$1.55$2.78
Distance from 52-week high-59.02%-88.47%
Analyst consensusnonenone
Avg. price target upside+210.08%+1248.42%
Average volume79.46K164.88K
Shares outstanding4.58M9.00M
Employees4010
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NXTC has outperformed PMN by 31.3 percentage points over the past year.

About NextCure

NXTC stock →

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

About ProMIS Neurosciences

PMN stock →

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

NXTC vs PMN FAQ

Which is bigger, NextCure or ProMIS Neurosciences?

NextCure (NXTC) is larger, with a market capitalization of $29.53M compared with $28.43M for ProMIS Neurosciences (PMN).

Which stock has performed better over the past year, NXTC or PMN?

NXTC returned -38.63% over the past 12 months, compared with -69.90% for PMN (price return, excluding dividends). Past performance does not predict future results.

Are NextCure and ProMIS Neurosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons